Takeda Gastric Cancer Drug Trial: Survival Reaches 10.2 Months
The Takeda gastric cancer drug trial found arcotatug tavatecan lifted median survival to 10.2 months versus 6.9. Results, safety and open questions.
The Takeda gastric cancer drug trial found arcotatug tavatecan lifted median survival to 10.2 months versus 6.9. Results, safety and open questions.
The Roche divarasib Phase 3 trial cut the risk of death by 44% in previously treated KRAS G12C lung cancer. Survival, response and safety data.
Bepirovirsen market to reach USD 2.12 billion by 2035 at 29.6% CAGR after Hibsago FDA approval. Segments, regional outlook, competitors and adoption hurdles.
The Paras Healthcare IPO subscription closed at 2.34 times. Category-wise demand, allotment on 26 October and the expected 28 October listing.
The Talkiatry therapy services nationwide now cover all 50 US states, the company says. What is offered, the claims and what remains unclear.
The healthcare AI adoption survey 2026 finds 91% of 525 clinical leaders want AI training, yet governance gaps remain. Key figures and caveats.
The FDA prescription drug software guidance is final: drug-linked app output counts as labeling. What it covers, what changed and what is unclear.
The Redesign Health ARC Global merger values the combined company at about $2B, per a source, and includes a planned AVIA purchase. What is confirmed.
The BD Alaris infusion set FDA alert covers Cardinal Health Presource kits. What the FDA says is wrong, who is at risk and what it recommends.
The global healthcare AI regulatory network gains Poland as its second EU member. What the HealthAI network does and what remains unsettled.